PURPOSE: To determine optimum periods for (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) examination in subjects with suspected acute myocarditis, we compared (18)F-FDG PET with endomyocardial biopsy (EMB) using the latest definition of (18)F-FDG PET for inflammatory left ventricular (LV) myocardium. MATERIALS AND METHODS: Retrospective analysis of 29 subjects (18 male, 48 ± 18 years) who have symptoms or LV dysfunction underwent both (18)F-FDG PET (Advance NXi, GE-Healthcare) under fasting conditions and EMB from LV posterior wall within 3 months. RESULTS: When we defined (18)F-FDG PET positive inflammatory LV posterior wall as 'focal on diffuse' pattern, sensitivity, specificity, and positive predictive values (PPV), and negative predictive values (NPV) of (18)F-FDG PET for detecting active inflammatory LV posterior wall compared with EMB were 46.2, 81.3, 66.7, and 65.0%, respectively. Receiver operating characteristic curve of periods (days) between onset of clinically suspected acute myocarditis and performance of (18)F-FDG PET for detecting inflammatory LV posterior wall demonstrated 17 days as a best cut off values with area under the curve (0.497, P=0.982) with sensitivity=21.1% and specificity=100%. Sensitivity, specificity, PPV and NPV of (18)F-FDG PET for detecting inflammatory LV posterior wall on EMB were all 100% when (18)F-FDG PET was performed at 1-14 days after onset of suspected acute myocarditis. CONCLUSIONS: In our definition, (18)F-FDG PET showed excellent agreement with EMB for detecting active inflammatory LV posterior wall in subjects with clinically suspected active acute myocarditis. If possible, (18)F-FDG PET should be performed within 14 days after the onset to maintain high diagnostic accuracy compared with EMB.
PURPOSE: To determine optimum periods for (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) examination in subjects with suspected acute myocarditis, we compared (18)F-FDG PET with endomyocardial biopsy (EMB) using the latest definition of (18)F-FDG PET for inflammatory left ventricular (LV) myocardium. MATERIALS AND METHODS: Retrospective analysis of 29 subjects (18 male, 48 ± 18 years) who have symptoms or LV dysfunction underwent both (18)F-FDG PET (Advance NXi, GE-Healthcare) under fasting conditions and EMB from LV posterior wall within 3 months. RESULTS: When we defined (18)F-FDG PET positive inflammatory LV posterior wall as 'focal on diffuse' pattern, sensitivity, specificity, and positive predictive values (PPV), and negative predictive values (NPV) of (18)F-FDG PET for detecting active inflammatory LV posterior wall compared with EMB were 46.2, 81.3, 66.7, and 65.0%, respectively. Receiver operating characteristic curve of periods (days) between onset of clinically suspected acute myocarditis and performance of (18)F-FDG PET for detecting inflammatory LV posterior wall demonstrated 17 days as a best cut off values with area under the curve (0.497, P=0.982) with sensitivity=21.1% and specificity=100%. Sensitivity, specificity, PPV and NPV of (18)F-FDG PET for detecting inflammatory LV posterior wall on EMB were all 100% when (18)F-FDG PET was performed at 1-14 days after onset of suspected acute myocarditis. CONCLUSIONS: In our definition, (18)F-FDG PET showed excellent agreement with EMB for detecting active inflammatory LV posterior wall in subjects with clinically suspected active acute myocarditis. If possible, (18)F-FDG PET should be performed within 14 days after the onset to maintain high diagnostic accuracy compared with EMB.
Authors: Patrick Krumm; Stefanie Mangold; Sergios Gatidis; Konstantin Nikolaou; Felix Nensa; Fabian Bamberg; Christian la Fougère Journal: Jpn J Radiol Date: 2018-03-10 Impact factor: 2.374
Authors: Luiz Eduardo Mastrocola; Barbara Juarez Amorim; João Vicente Vitola; Simone Cristina Soares Brandão; Gabriel Blacher Grossman; Ronaldo de Souza Leão Lima; Rafael Willain Lopes; William Azem Chalela; Lara Cristiane Terra Ferreira Carreira; José Roberto Nolasco de Araújo; Cláudio Tinoco Mesquita; José Claudio Meneghetti Journal: Arq Bras Cardiol Date: 2020-02 Impact factor: 2.000
Authors: Benjamin P Geisler; Roy A Raad; Diana Esaian; Elad Sharon; David R Schwartz Journal: J Immunother Cancer Date: 2015-02-17 Impact factor: 13.751
Authors: Shirjel R Alam; Anoop S V Shah; Kevin O Ombati; Edward Nganga; Samuel Gitau; Khalid Makhdomi; Michael H Chung; Sudhir Vinayak Journal: BMC Cardiovasc Disord Date: 2021-05-08 Impact factor: 2.298
Authors: Agata Tymińska; Krzysztof Ozierański; Aleksandra Skwarek; Agnieszka Kapłon-Cieślicka; Anna Baritussio; Marcin Grabowski; Renzo Marcolongo; Alida Lp Caforio Journal: J Pers Med Date: 2022-01-30